CN113717900A - 一株发酵乳杆菌及其应用 - Google Patents
一株发酵乳杆菌及其应用 Download PDFInfo
- Publication number
- CN113717900A CN113717900A CN202111175711.9A CN202111175711A CN113717900A CN 113717900 A CN113717900 A CN 113717900A CN 202111175711 A CN202111175711 A CN 202111175711A CN 113717900 A CN113717900 A CN 113717900A
- Authority
- CN
- China
- Prior art keywords
- lactobacillus fermentum
- cfu
- strain
- food
- lactobacillus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000186840 Lactobacillus fermentum Species 0.000 title claims abstract description 92
- 229940012969 lactobacillus fermentum Drugs 0.000 title claims abstract description 92
- 239000000049 pigment Substances 0.000 claims abstract description 28
- 235000013305 food Nutrition 0.000 claims abstract description 23
- 241000607265 Vibrio vulnificus Species 0.000 claims abstract description 16
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 claims abstract description 14
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 claims abstract description 13
- 229940068041 phytic acid Drugs 0.000 claims abstract description 13
- 235000002949 phytic acid Nutrition 0.000 claims abstract description 12
- 239000000467 phytic acid Substances 0.000 claims abstract description 12
- 239000003814 drug Substances 0.000 claims abstract description 9
- 230000000593 degrading effect Effects 0.000 claims abstract description 8
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 8
- 238000009629 microbiological culture Methods 0.000 claims abstract description 4
- 239000001963 growth medium Substances 0.000 claims description 21
- 241000894006 Bacteria Species 0.000 claims description 20
- 230000001580 bacterial effect Effects 0.000 claims description 17
- 235000013402 health food Nutrition 0.000 claims description 5
- 238000012258 culturing Methods 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000000877 morphologic effect Effects 0.000 claims 1
- 238000004321 preservation Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 25
- 108010011619 6-Phytase Proteins 0.000 abstract description 20
- 229940085127 phytase Drugs 0.000 abstract description 20
- 230000012010 growth Effects 0.000 abstract description 17
- 239000003833 bile salt Substances 0.000 abstract description 11
- 239000002253 acid Substances 0.000 abstract description 7
- 244000052616 bacterial pathogen Species 0.000 abstract description 6
- 241000186660 Lactobacillus Species 0.000 abstract description 5
- 229940039696 lactobacillus Drugs 0.000 abstract description 5
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000015556 catabolic process Effects 0.000 description 26
- 238000006731 degradation reaction Methods 0.000 description 26
- 239000000243 solution Substances 0.000 description 17
- 239000001052 yellow pigment Substances 0.000 description 14
- 235000005979 Citrus limon Nutrition 0.000 description 13
- 244000131522 Citrus pyriformis Species 0.000 description 13
- 102000004190 Enzymes Human genes 0.000 description 11
- 108090000790 Enzymes Proteins 0.000 description 11
- 229940088598 enzyme Drugs 0.000 description 11
- 238000009630 liquid culture Methods 0.000 description 11
- 240000001592 Amaranthus caudatus Species 0.000 description 10
- 235000009328 Amaranthus caudatus Nutrition 0.000 description 10
- 241001052560 Thallis Species 0.000 description 10
- 235000012735 amaranth Nutrition 0.000 description 10
- 239000004178 amaranth Substances 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 235000012730 carminic acid Nutrition 0.000 description 8
- 244000005700 microbiome Species 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 7
- 235000012741 allura red AC Nutrition 0.000 description 7
- 239000004191 allura red AC Substances 0.000 description 7
- CEZCCHQBSQPRMU-UHFFFAOYSA-L chembl174821 Chemical compound [Na+].[Na+].COC1=CC(S([O-])(=O)=O)=C(C)C=C1N=NC1=C(O)C=CC2=CC(S([O-])(=O)=O)=CC=C12 CEZCCHQBSQPRMU-UHFFFAOYSA-L 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 239000011574 phosphorus Substances 0.000 description 7
- 229910052698 phosphorus Inorganic materials 0.000 description 7
- 235000013373 food additive Nutrition 0.000 description 6
- 239000002778 food additive Substances 0.000 description 6
- 210000001035 gastrointestinal tract Anatomy 0.000 description 6
- 235000020256 human milk Nutrition 0.000 description 6
- 238000011081 inoculation Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 5
- 239000005695 Ammonium acetate Substances 0.000 description 5
- 229940043376 ammonium acetate Drugs 0.000 description 5
- 235000019257 ammonium acetate Nutrition 0.000 description 5
- 230000033228 biological regulation Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 238000001556 precipitation Methods 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- -1 phytic acid Chemical compound 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- SRBFZHDQGSBBOR-SOOFDHNKSA-N D-ribopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@@H]1O SRBFZHDQGSBBOR-SOOFDHNKSA-N 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 108090000371 Esterases Proteins 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000031700 light absorption Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- AYRXSINWFIIFAE-UDKQPYHCSA-N (2r,3s,4r,5r)-2,3,4,5-tetrahydroxy-6-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexanal Chemical compound OC[C@H]1O[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)[C@H](O)[C@@H](O)[C@@H]1O AYRXSINWFIIFAE-UDKQPYHCSA-N 0.000 description 2
- XUCIJNAGGSZNQT-JHSLDZJXSA-N (R)-amygdalin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@@H](C#N)C=2C=CC=CC=2)O1 XUCIJNAGGSZNQT-JHSLDZJXSA-N 0.000 description 2
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 2
- 102000013563 Acid Phosphatase Human genes 0.000 description 2
- 108010051457 Acid Phosphatase Proteins 0.000 description 2
- PLXMOAALOJOTIY-FPTXNFDTSA-N Aesculin Natural products OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H]1Oc2cc3C=CC(=O)Oc3cc2O PLXMOAALOJOTIY-FPTXNFDTSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- ATSKDYKYMQVTGH-DNCUWRPASA-N Amaranthin Natural products O=C(O)[C@@H]1[C@@H](O)[C@H](O)[C@H](O)[C@H](O[C@@H]2[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]2Oc2c(O)cc3/[N+](=C\C=C\4/C=C(C(=O)O)N[C@@H](C(=O)O)C/4)/[C@@H](C(=O)[O-])Cc3c2)O1 ATSKDYKYMQVTGH-DNCUWRPASA-N 0.000 description 2
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 2
- WNBCMONIPIJTSB-BGNCJLHMSA-N Cichoriin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1)c1c(O)cc2c(OC(=O)C=C2)c1 WNBCMONIPIJTSB-BGNCJLHMSA-N 0.000 description 2
- GUBGYTABKSRVRQ-UHFFFAOYSA-N D-Cellobiose Natural products OCC1OC(OC2C(O)C(O)C(O)OC2CO)C(O)C(O)C1O GUBGYTABKSRVRQ-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 2
- RFSUNEUAIZKAJO-VRPWFDPXSA-N D-Fructose Natural products OC[C@H]1OC(O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-VRPWFDPXSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
- QWIZNVHXZXRPDR-UHFFFAOYSA-N D-melezitose Natural products O1C(CO)C(O)C(O)C(O)C1OC1C(O)C(CO)OC1(CO)OC1OC(CO)C(O)C(O)C1O QWIZNVHXZXRPDR-UHFFFAOYSA-N 0.000 description 2
- LKDRXBCSQODPBY-OEXCPVAWSA-N D-tagatose Chemical compound OCC1(O)OC[C@@H](O)[C@H](O)[C@@H]1O LKDRXBCSQODPBY-OEXCPVAWSA-N 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 2
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 2
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 2
- DKXNBNKWCZZMJT-UHFFFAOYSA-N O4-alpha-D-Mannopyranosyl-D-mannose Natural products O=CC(O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O DKXNBNKWCZZMJT-UHFFFAOYSA-N 0.000 description 2
- 206010048685 Oral infection Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- NGFMICBWJRZIBI-JZRPKSSGSA-N Salicin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O1)c1c(CO)cccc1 NGFMICBWJRZIBI-JZRPKSSGSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 2
- 108010030291 alpha-Galactosidase Proteins 0.000 description 2
- 102000005840 alpha-Galactosidase Human genes 0.000 description 2
- 108010028144 alpha-Glucosidases Proteins 0.000 description 2
- NGFMICBWJRZIBI-UHFFFAOYSA-N alpha-salicin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UHFFFAOYSA-N 0.000 description 2
- ATSKDYKYMQVTGH-POBNKHOBSA-N amaranthin Chemical compound [N+]1([C@H](C([O-])=O)CC=2C=C(C(=CC=21)O)O[C@@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@H](O1)C(O)=O)O)O)CO)=C\C=C1/C[C@@H](C(O)=O)NC(C(O)=O)=C1 ATSKDYKYMQVTGH-POBNKHOBSA-N 0.000 description 2
- 229940089837 amygdalin Drugs 0.000 description 2
- YZLOSXFCSIDECK-UHFFFAOYSA-N amygdalin Natural products OCC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC(C#N)c3ccccc3 YZLOSXFCSIDECK-UHFFFAOYSA-N 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 229960000271 arbutin Drugs 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- 102000005936 beta-Galactosidase Human genes 0.000 description 2
- 102000006995 beta-Glucosidase Human genes 0.000 description 2
- 108010047754 beta-Glucosidase Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 210000003022 colostrum Anatomy 0.000 description 2
- 235000021277 colostrum Nutrition 0.000 description 2
- 229960003067 cystine Drugs 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- XHCADAYNFIFUHF-TVKJYDDYSA-N esculin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC2=C1OC(=O)C=C2 XHCADAYNFIFUHF-TVKJYDDYSA-N 0.000 description 2
- 229940093496 esculin Drugs 0.000 description 2
- AWRMZKLXZLNBBK-UHFFFAOYSA-N esculin Natural products OC1OC(COc2cc3C=CC(=O)Oc3cc2O)C(O)C(O)C1O AWRMZKLXZLNBBK-UHFFFAOYSA-N 0.000 description 2
- YGHHWSRCTPQFFC-UHFFFAOYSA-N eucalyptosin A Natural products OC1C(O)C(O)C(CO)OC1OC1C(OC(C#N)C=2C=CC=CC=2)OC(CO)C(O)C1O YGHHWSRCTPQFFC-UHFFFAOYSA-N 0.000 description 2
- 210000004211 gastric acid Anatomy 0.000 description 2
- 229940050410 gluconate Drugs 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 230000006799 invasive growth in response to glucose limitation Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 229960002160 maltose Drugs 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- QWIZNVHXZXRPDR-WSCXOGSTSA-N melezitose Chemical compound O([C@@]1(O[C@@H]([C@H]([C@@H]1O[C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O)CO)CO)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QWIZNVHXZXRPDR-WSCXOGSTSA-N 0.000 description 2
- DLRVVLDZNNYCBX-ABXHMFFYSA-N melibiose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-ABXHMFFYSA-N 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- HOVAGTYPODGVJG-VEIUFWFVSA-N methyl alpha-D-mannoside Chemical compound CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O HOVAGTYPODGVJG-VEIUFWFVSA-N 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229950006780 n-acetylglucosamine Drugs 0.000 description 2
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 239000006041 probiotic Substances 0.000 description 2
- 230000000529 probiotic effect Effects 0.000 description 2
- 235000018291 probiotics Nutrition 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 2
- NGFMICBWJRZIBI-UJPOAAIJSA-N salicin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UJPOAAIJSA-N 0.000 description 2
- 229940120668 salicin Drugs 0.000 description 2
- CQRYARSYNCAZFO-UHFFFAOYSA-N salicyl alcohol Chemical compound OCC1=CC=CC=C1O CQRYARSYNCAZFO-UHFFFAOYSA-N 0.000 description 2
- 239000013535 sea water Substances 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 229960004793 sucrose Drugs 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- 240000006439 Aspergillus oryzae Species 0.000 description 1
- 235000002247 Aspergillus oryzae Nutrition 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 101000588395 Bacillus subtilis (strain 168) Beta-hexosaminidase Proteins 0.000 description 1
- 208000031729 Bacteremia Diseases 0.000 description 1
- 108010062877 Bacteriocins Proteins 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 239000006142 Luria-Bertani Agar Substances 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- PYMYPHUHKUWMLA-VAYJURFESA-N aldehydo-L-arabinose Chemical compound OC[C@H](O)[C@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-VAYJURFESA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- WLDHEUZGFKACJH-UHFFFAOYSA-K amaranth Chemical compound [Na+].[Na+].[Na+].C12=CC=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(O)=C1N=NC1=CC=C(S([O-])(=O)=O)C2=CC=CC=C12 WLDHEUZGFKACJH-UHFFFAOYSA-K 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940040526 anhydrous sodium acetate Drugs 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000433 anti-nutritional effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- DGQLVPJVXFOQEV-JNVSTXMASA-N carminic acid Chemical compound OC1=C2C(=O)C=3C(C)=C(C(O)=O)C(O)=CC=3C(=O)C2=C(O)C(O)=C1[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O DGQLVPJVXFOQEV-JNVSTXMASA-N 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- JBTHDAVBDKKSRW-UHFFFAOYSA-N chembl1552233 Chemical compound CC1=CC(C)=CC=C1N=NC1=C(O)C=CC2=CC=CC=C12 JBTHDAVBDKKSRW-UHFFFAOYSA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000021245 dietary protein Nutrition 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000005553 drilling Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000000459 effect on growth Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 235000021001 fermented dairy product Nutrition 0.000 description 1
- 229960002413 ferric citrate Drugs 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 229960003284 iron Drugs 0.000 description 1
- NPFOYSMITVOQOS-UHFFFAOYSA-K iron(III) citrate Chemical compound [Fe+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NPFOYSMITVOQOS-UHFFFAOYSA-K 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 229940040511 liver extract Drugs 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 229910000357 manganese(II) sulfate Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000002366 mineral element Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 239000006872 mrs medium Substances 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- ASXCJONOVQSZRF-LXGUWJNJSA-N n-[(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl]acetamide Chemical compound CC(=O)NC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO ASXCJONOVQSZRF-LXGUWJNJSA-N 0.000 description 1
- 230000001937 non-anti-biotic effect Effects 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000001878 scanning electron micrograph Methods 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229940073450 sudan red Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000001040 synthetic pigment Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- YWYZEGXAUVWDED-UHFFFAOYSA-N triammonium citrate Chemical compound [NH4+].[NH4+].[NH4+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O YWYZEGXAUVWDED-UHFFFAOYSA-N 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
- A23L5/40—Colouring or decolouring of foods
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
- C12Y301/03008—3-Phytase (3.1.3.8)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
- C12Y301/03026—4-Phytase (3.1.3.26), i.e. 6-phytase
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/143—Fermentum
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
本发明公开了一株发酵乳杆菌(Lactobacillus fermentum),所述菌株保藏名称为发酵乳杆菌B153,于2018年9月10日保藏在中国微生物菌种保藏管理委员会普通微生物中心,保藏编号为:CGMCC No.16454。本发明还公开了该发酵乳杆菌在制备抑制创伤弧菌药物、保健食品或普通食品中的应用,在降解偶氮类人工合成色素中的应用,以及在制备低植酸产品中的应用。本发明提供的发酵乳杆菌B153具有很强的耐酸耐胆盐能力和较高的植酸酶活力,能够显著抑制致病菌创伤弧菌的生长;该菌株能够显著降解偶氮类人工合成食用色素。因此,本发明提供的发酵乳杆菌B153具有较高的社会应用价值。
Description
技术领域
本发明涉及微生物菌株及其应用技术领域,具体涉及一株发酵乳杆菌及其应用。
背景技术
植酸即肌醇六磷酸,又称六磷酸肌醇,由一分子肌醇与六分子磷酸结合而成,是植物体内磷的主要储存形式(占总磷的18%~88%)。植酸在禾谷类、豆科作物中广泛存在,也是植物体内的主要抗营养因子。植酸盐形式的磷不容易可被单胃动物利用,并会导致集约化地区畜牧生产磷污染的问题。植酸与必需膳食矿物质和蛋白质之间的相互作用被认为是限制谷物和豆类对人体和动物营养价值的主要因素之一。植酸可与多价阳离子结合,形成不溶性的复合物,降低了无机盐与微量元素的生物利用率,继而引起人体和动物相应的金属营养元素缺乏症。在动物消化道的酸性条件下,植酸可与二价金属离子(Zn2+、Cu2+、Fe2+、Mn2 +、Ca2+等阳离子)、带正电的蛋白质、氨基酸发生反应,生成植酸—金属阳离子的络合物、植酸•蛋白质、植酸•金属阳离子•蛋白质(氨基酸)的复合物,上述络合物或复合物不仅基团之间的亲和力强,且其本身难以溶解,不仅影响磷的利用率,同时还影响矿物元素、蛋白质、氨基酸的利用率,甚至对淀粉酶、脂肪酶的活性均有抑制作用。因此,科学家们尝试通过植酸酶来水解膳食植酸以提高膳食营养素的利用率并减少动物中磷的排泄量。自然界中微生物是植酸酶的主要来源,科学家们从自然界中发现了多种产植酸酶的微生物,如细菌(假单胞菌、枯草芽孢杆菌)、霉菌(黑曲霉、米曲霉)和真菌等。然而,目前为止所获得的产植酸酶微生物大部分来源于土壤,并有少部分来自动物肠道,国内外尚未见到来源于人类母乳的产植酸酶微生物的相关报道。
创伤弧菌广泛分布在海水中,创伤弧菌可从牡蛎等海产品中分离得到。该菌主要通过伤口接触海水造成感染,也可经口感染。经伤口感染时可导致蜂窝织炎及骨髓炎等多种炎症,经口感染时常迅速导致菌血症或败血症。感染本菌后如不及时治疗,病死率很高。目前,对于这些致病菌主要还是采用抗生素进行抑菌治疗,但是抗生素存在耐药性的问题,因此,开发能够有效抑制创伤弧菌生长的非抗生素类产品具有重要意义。
偶氮类合成色素因合成工艺简单、成本低、染色性能突出等优点,被广泛的应用在食品、药品和化妆品等领域。其种类有很多,熟知的有苏丹红、柠檬黄、日落黄、柠檬黄、苋菜红、胭脂红和诱惑红等。目前已有不少研究发现了偶氮类色素的毒性作用,如使肝细胞生长异常,影响酯酶同工酶的表达,以及致突变作用等,因此多数偶氮色素已被禁止添加到食物中。我国2014年最新颁布的《食品添加剂使用标准(GB276 0-2014)》中对允许使用的柠檬黄、日落黄、柠檬黄、苋菜红、胭脂红和诱惑红等11种偶氮类色素在食品中的限量及使用范围做了明确的规定,严禁超量或超范围添加。
发酵乳杆菌(Lactobacillus fermentum)是我国批准的可用于普通食品的菌种之一。发酵乳杆菌广泛存在于人体口腔及肠道,发酵乳制品和植物原料发酵物等诸多环境中,它具有乳杆菌属调节肠道和增强免疫力等益生功能,其代谢产生的细菌素具有优良的抑菌性能。目前,发酵乳杆菌的益生功能及其在食品、医疗保健等领域发挥的作用已受到食品届内学者的高度重视。目前为止,行业内未见来源于人类母乳的高产植酸酶的发酵乳杆菌,也未见将发酵乳杆菌开发用于抑制特定致病菌创伤弧菌的药物、保健食品或普通食品的相关报道,亦未见将发酵乳杆菌用于降解偶氮类人工合成食用色素的相关报道。
发明内容
本发明的目的是提供一株发酵乳杆菌及其应用,开发了一株能够产植酸酶,还能够显著抑制创伤弧菌生长,且能够降解偶氮类人工合成食用色素的菌株。
本发明的目的是通过以下技术方案实现的:一株发酵乳杆菌,所述菌株保藏名称为发酵乳杆菌(Lactobacillus fermentum)B153,于2018年9月10日保藏在中国微生物菌种保藏管理委员会普通微生物中心,保藏编号为:CGMCC No.16454。保藏单位地址:北京市朝阳区北辰西路1号院3号,中国科学院微生物研究所,邮编:100101。
本发明提供的发酵乳杆菌B153分离自人类母乳,菌落特征为:在MRS平板培养基上培养24~48 h后,菌落呈圆形,乳白色,表面光滑、隆起,边缘整齐,不透明,菌体呈杆状,大小为0.3~0.6 × 1.0~3.0 μm;能够生长的pH值为4.0~9.0,最适生长pH为6.0,能够生长的温度为20~45℃,最适生长温度40℃;能够利用的糖类包括:L-阿拉伯糖、核糖、D-半乳糖、D-葡萄糖、D-果糖、D-甘露糖、甘露醇、山梨醇、α-甲基-D-吡喃甘露醇苷、N-乙酰葡萄糖胺、苦杏仁苷、熊果苷、七叶苷柠檬酸铁、水杨苷(柳醇)、D-纤维二糖、D-麦芽糖、D-乳糖、D-密二糖、D-蔗糖、海藻糖、D-松三糖、D-棉子糖、D-龙胆二糖、D-塔格糖、D-土伦糖和葡萄糖酸盐;能够分泌白氨酸芳胺酶、缬氨酸芳胺酶、胱氨酸芳胺酶、酸性磷酸酶、萘酚-AS-BI-磷酸水解酶、α-半乳糖苷酶、β-半乳糖苷酶、α-葡萄糖苷酶、β-葡萄糖苷酶、N-乙酰-葡萄糖胺酶、酯酶、类脂肪酶和类脂酶。该菌株能够产植酸酶,并显著抑制致病菌创伤弧菌的生长,还能够降解偶氮类人工合成食用色素。
本发明所述的发酵乳杆菌在制备抑制创伤弧菌药物、保健食品或普通食品中的应用;所述药物、保健食品或普通食品中所含发酵乳杆菌B153的活菌数为1.0×106-5.0×1011 cfu/mL或1.0×106-5.0×1011 cfu/g,优选活菌数为2.0×106-2.0×108 cfu/mL或2.0×106-2.0×108 cfu/g,最优选活菌数为2.0×107 cfu/mL或2.0×107 cfu/g。
本发明所述的发酵乳杆菌在制备低植酸产品中的应用:所述产品中所含发酵乳杆菌B153的活菌数为1.0×106-5.0×1011 cfu/mL或1.0×106-5.0×1011 cfu/g。
本发明所述的发酵乳杆菌在降解偶氮类人工合成食用色素的应用,具体是将所述发酵乳杆菌B153添加到含有偶氮类人工合成食用色素的培养基中,所述基质中所含发酵乳杆菌B153的活菌数为1.0×106 ~5.0×1010 cfu/mL或1.0×106 ~5.0×1010 cfu/g,优选活菌数为活菌数为1.0 ×10 6 ~ 1.0×109 cfu/mL或1.0 ×10 6 ~ 1.0×109 cfu/g,最优选活菌数1.0×109 cfu/mL或1.0×109 cfu/g。
本发明的有益效果在于:本发明提供的发酵乳杆菌B153分离自人类母乳,安全性高,该菌株能够产植酸酶,为低植酸产品的制备提供了新的选择;该菌株能够显著抑制致病菌创伤弧菌的生长;该菌株还能够降解偶氮类人工合成食用色素,为偶氮类人工合成食用色素的降解制剂提供了新的选择。因此,本发明提供的发酵乳杆菌B153具有较高的社会应用价值。
附图说明
图1为发酵乳杆菌B153的菌落形态。
图2为发酵乳杆菌B153的扫描电镜图。
图3为发酵乳杆菌B153在不同温度下的生长曲线。
图4为发酵乳杆菌B153在不同pH值下的生长曲线。
具体实施方式
以下的实施例便于更好地理解本发明,但并不限定本发明。下述实施例中的实验方法,若未特别指明,实施例中的培养基及实验条件均为常规培养基和实验条件。实施例中所用的试验材料、试剂等,如无特殊说明,均可从商业途径得到。
实施例1 发酵乳杆菌(Lactobacillus fermentum)B153的分离与鉴定
1、菌株分离
从一名来自中国的健康妇女获取母乳,将获取的新鲜初乳置于超净工作台中用无菌的PBS溶液(浓度为10 mM)稀释,将未稀释的乳汁和稀释5倍的乳汁分别分配到BBL平板培养基中,在37℃下恒温厌氧培养,直至菌落出现,用接种针挑取边缘生长良好的细菌,接种于新的BBL平板培养基上,待新接种的菌长成菌落后,再挑取其边缘的内生菌划线培养,如此反复得到纯化,直到得到单菌落,命名其为菌株B153。
其中BBL平板培养基配方为:蛋白胨15.0 g/L、酵母粉2.0 g/L、葡萄糖20.0 g/L、可溶性淀粉0.5 g/L、NaCl 5.0 g/L、半胱氨酸 10.0 mL/L、西红柿浸出液 400 mL/L、吐温80 1.0 mL/L、肝提取液80.0 mL/L、琼脂20.0 g/L、蒸馏水520 mL/L,pH值为6.0,在121℃灭菌20 min。
2、菌株鉴定
(1)菌落及菌体的形态观察:将菌株B153在MRS平板培养基上进行划线培养,在37℃恒温厌氧培养24~48 h后,菌落呈圆形,乳白色,表面光滑、隆起,边缘整齐,不透明,菌落形态见图1。在扫描电子显微镜下观察,菌体呈杆状,大小为0.3~0.6 × 1.0~3.0 μm,其扫描电镜图为图2。
其中MRS平板培养基配方为:胰蛋白胨10.0 g/L、牛肉粉5.0 g/L、酵母粉4.0 g/L、葡萄糖20.0 g/L、吐温80 1.0 mL/L、K2HPO4•3H2O 1.5 g/L、无水乙酸钠3.0 g/L、柠檬酸铵2.0 g/L、MgSO4•7H2O 0.2 g/L、MnSO4•H2O 0.04 g/L,琼脂15.0 g/L。pH值为6.0,在121℃灭菌20 min。
(2)菌株B153的生长特征观察:将B153菌液(浓度为1.0×107 cfu/mL)按体积比3.0%的接种量接种于MRS液体培养基中,置于不同温度(10℃-50℃)下厌氧培养24 h,发现菌株在10℃或50℃下基本不能生长,在30℃~40℃环境下生长良好,最适生长温度为40℃(见图3);置于不同初始pH值(2.0~12.0)环境下厌氧培养24 h,发现菌株在pH值范围为3.0~11.0的环境中菌株能够生长,最适生长pH值为6.0(见图4)。
(3)菌株B153的分子生物学鉴定:采用细菌全基因组快速抽提试剂盒(购自天根生化科技(北京)有限公司),提取菌株B153的全基因组,通过选用细菌16S rDNA通用引物27F和1492R进行PCR,然后测序分析。通用引物27F和1492R核苷酸序列如下:
27F(SEQ ID No.1):5’-AGAGTTTGATCCTGGCTCAG-3’
1492R(SEQ ID No.2):5’-GGTTACCTTGTTACGACTT-3’
测序结果经BLAST比对,鉴定该菌株为发酵乳杆菌,基因序列如SEQ ID No.3所示,命名为:发酵乳杆菌(Lactobacillus fermentum)B153,于2018年9月10日保藏在中国微生物菌种保藏管理委员会普通微生物中心,保藏编号为:CGMCC No.16454。保藏单位地址:北京市朝阳区北辰西路1号院3号,中国科学院微生物研究所,邮编:100101。
实施例2 发酵乳杆菌(Lactobacillus fermentum)B153的耐酸及耐胆盐能力
将活化好的菌株制成悬液,取1.0 mL菌悬液(浓度为2.0×108 cfu/mL)分别接种至9.0 mL的pH为2.0、2.5、3.0或胆盐浓度为1.0、2.0、3.0 g/L的MRS液体培养基中,37℃厌氧培养4 h,分别在0 h和4 h平板计数法测定活菌数,计算存活率(%)。
存活率(%)=(4 h的活菌数/0 h的活菌数)×100。
表1发酵乳杆菌HLX37的耐酸耐胆盐能力
表1显示,发酵乳杆菌B153在pH为2.0、2.5、3.0和3.5条件下的4 h存活率分别为56.9%±1.8%、94.5%±3.3%、94.9%±2.9%和108.0%±6.4%,说明其具有非常强的耐酸能力。同时,发酵乳杆菌B153在1.0、2.0、3.0和4.0 g/L胆盐浓度下的存活率分别达101.9%±5.1%、67.7%±2.7%、39.6%±1.5%和39.1%±1.2%,说明其具有较强的耐胆盐能力。已知人体胃部的pH范围基本在2.0~3.0,微生物随食物或唾液进入胃部以后,大多数会被胃酸杀死,只有少数耐酸的微生物才能存活下来进入小肠。小肠是人体胆固醇合成和吸收的重要场所,同时也是乳酸菌发挥其降胆固醇作用的主要部位,但肠道内的胆盐(浓度范围0.3~3.0g/L)对微生物的生长也具有一定的抑制作用。因此,乳酸菌要在体内发挥降胆固醇功效,要求其能够耐受胃肠道的低pH和小肠中的胆汁盐等逆境。本研究发现,发酵乳杆菌B153在pH为2.5~3.0环境下的存活率仍能达到90%以上,且在1.0~4.0 g/L胆盐浓度范围内也能够生长。以上数据结果表明发酵乳杆菌B153具有较强的耐酸耐胆盐能力,能够顺利通过胃酸环境到达肠内并在肠内存活。
实施例3 发酵乳杆菌(Lactobacillus fermentum)B153对糖类的利用性
应用API50CHL 试剂盒(Biomerieux,法国)检测实施例1中分离的菌株B153对糖类的利用性,结果(表2)显示:本发明发酵乳杆菌B153能够利用L-阿拉伯糖、核糖、D-半乳糖、D-葡萄糖、D-果糖、D-甘露糖、甘露醇、山梨醇、α-甲基-D-吡喃甘露醇苷、N-乙酰葡萄糖胺、苦杏仁苷、熊果苷、七叶苷柠檬酸铁、水杨苷(柳醇)、D-纤维二糖、D-麦芽糖、D-乳糖、D-密二糖、D-蔗糖、海藻糖、D-松三糖、D-棉子糖、D-龙胆二糖、D-塔格糖、D-土伦糖和葡萄糖酸盐。
表2 应用API50CHL 试剂盒检测菌株B153对糖类的利用性结果
备注:+表示阳性结果,说明菌株能够利用受试底物;-表示阴性结果,说明菌株不能利用受试底物。
实施例4 发酵乳杆菌(Lactobacillus fermentum)B153的酶活性
应用APIZYM 试剂盒(Biomerieux,法国)检测实施例1 中分离的菌株B153的酶活性,结果(表3)显示:本发明发酵乳杆菌B153能够分泌白氨酸芳胺酶、缬氨酸芳胺酶、胱氨酸芳胺酶、酸性磷酸酶、萘酚-AS-BI-磷酸水解酶、α-半乳糖苷酶、β-半乳糖苷酶、α-葡萄糖苷酶、β-葡萄糖苷酶、N-乙酰-葡萄糖胺酶、酯酶、类脂肪酶和类脂酶。
表3 应用APIZYM 试剂盒检测B153的酶活性结果
备注:分值0-1表示为阴性反应;分值2表示反应微弱;分值为3-5表示阳性反应;颜色越深,分值越高。
实施例5 发酵乳杆菌B153的植酸酶活力
实验方法:取100 μL活化好的B153菌液(浓度为:2.0 × 107 cfu/mL)接种于5 mL的MRS培养基中,于第0 h、6 h、12 h、24 h、36 h、48 h和72 h取菌株培养液,离心(12000 g,10 min,4℃),收集上清液,采用《GBT18634-2009饲用植酸酶活性的测定-分光光度法》测定植酸酶活力,植酸酶活力单位(U)定义是以37℃下每小时生成1 μmol无机磷所需的酶量为一个活力单位。
实验结果如下:
表4 发酵乳杆菌B153在不同培养时间下的植酸酶活力
表4结果显示,发酵乳杆菌B153是一株能够产植酸酶的乳酸菌;随着培养时间的增加,发酵乳杆菌B153的植酸酶活力呈先增加后下降的变化趋势,在培养第24 h时,发酵乳杆菌B153的植酸酶活力达到最大,为3.14±0.26 U /mL。
实施例6 发酵乳杆菌B153对创伤弧菌生长的抑制试验
实验方法:以创伤弧菌(浓度为:1.0×106 cfu/mL)为指示菌,涂布于LB琼脂平板上,用无菌打孔器在平板上打直径为6 mm的加样孔,每组设置3个重复;在孔中加入100 μL的B153菌液(浓度为2.0×107 cfu/mL),于37℃生化培养箱中培养24 h。观察并记录抑菌圈大小。
实验结果如下:
表5 本发明发酵乳杆菌B153对创伤弧菌的抗菌活性
表5结果显示,B153菌液对创伤弧菌的显抑菌圈大小为1.4 cm,表明发酵乳杆菌B153对创伤弧菌的生长具有明显的抑制效果。
实施例7 发酵乳杆菌(Lactobacillus fermentum)B153在降解日落黄色素中的应用
实验方法:将菌株B153(菌体浓度为1.0×107 cfu/mL)按体积比5%的接种量分别接种于MRS液体培养基中,置于37℃下厌氧培养24 h后,离心收集菌体沉淀,经适当稀释调整,使菌体浓度分别为1.0×109 cfu/mL、1.0×108 cfu/mL、1.0×107 cfu/mL和1.0×106cfu/mL,同时根据《食品添加剂使用标准(GB276 0-2014)》规定,日落黄色素在食品中的最大允许使用量为0.05 g/kg,设置日落黄色素在含B153菌体的MRS液体培养基中的浓度分别为0.05、0.025和0.0125 g/L,于不同培养时间(3 h ~ 48 h)下取培养液,与1.5 g/L乙酸铵溶液按1:1比例稀释,在480 nm下测吸光值,按照下述公式计算降解率。
实验结果如下:
表6 不同培养时间下发酵乳杆菌B153菌株对日落黄色素的降解效果
表6结果显示,发酵乳杆菌B153菌株对日落黄色素有一定的降解效果,在培养时间为48 h,菌体浓度为1.0×109 cfu/mL,日落黄色素浓度为0.05 g/L时,B153菌株对日落黄色素的降解率达58.82%。
实施例8 发酵乳杆菌(Lactobacillus fermentum)B153在降解柠檬黄色素中的应用
实验方法:将菌株B153(菌体浓度为1.0×107 cfu/mL)按体积比5%的接种量分别接种于MRS液体培养基中,置于37℃下厌氧培养24 h后,离心收集菌体沉淀,经适当稀释调整,使菌体浓度分别为1.0×109 cfu/mL、1.0×108 cfu/mL、1.0×107 cfu/mL和1.0×106cfu/mL,同时根据《食品添加剂使用标准(GB276 0-2014)》规定,柠檬黄色素在食品中的最大允许使用量为0.05 g/kg,设置柠檬黄色素在含B153菌体的MRS液体培养基中的浓度分别为0.05、0.025和0.0125 g/L,于不同培养时间(3 h ~ 48 h)下取培养液,与1.5 g/L乙酸铵溶液按1:1比例稀释,在426 nm下测吸光值,按照下述公式计算降解率。
实验结果如下:
表7 不同培养时间下发酵乳杆菌B153菌株对柠檬黄色素的降解效果
表7结果显示,发酵乳杆菌B153菌株对柠檬黄色素具有一定的降解效果,在培养时间为48 h,菌体浓度为1.0×109 cfu/mL,柠檬黄色素浓度为0.05 g/L时,B153菌株对柠檬黄色素的降解率达40.95%。
实施例9 发酵乳杆菌(Lactobacillus fermentum)B153在降解苋菜红色素中的应用
实验方法:将菌株B153(菌体浓度为1.0×107 cfu/mL)按体积比5%的接种量分别接种于MRS液体培养基中,置于37℃下厌氧培养24 h后,离心收集菌体沉淀,经适当稀释调整,使菌体浓度分别为1.0×109 cfu/mL、1.0×108 cfu/mL、1.0×107 cfu/mL和1.0×106cfu/mL,同时根据《食品添加剂使用标准(GB276 0-2014)》规定,苋菜红色素在食品中的最大允许使用量为0.025 g/kg,设置苋菜红色素在含B153菌体的MRS液体培养基中的浓度分别为0.025、0.0125和0.00625 g/L,于不同培养时间(3 h ~ 48 h)下取培养液,与1.5 g/L乙酸铵溶液按1:1比例稀释,在518 nm下测吸光值,按照下述公式计算降解率。
实验结果如下:
表8 不同培养时间下发酵乳杆菌B153菌株对苋菜红色素的降解效果
表8结果显示,发酵乳杆菌B153菌株对苋菜红色素具有明显的降解效果,在培养时间为24 h、36 h和48 h,菌体浓度为1.0×109 cfu/mL,苋菜红色素浓度为0.025 g/L时,B153菌株对苋菜红色素的降解率超过50%,分别为58.09%、69.29%和74.07%。
实施例10 发酵乳杆菌(Lactobacillus fermentum)B153在降解胭脂红色素中的应用
实验方法:将菌株B153(菌体浓度为1.0×107 cfu/mL)按体积比5%的接种量分别接种于MRS液体培养基中,置于37℃下厌氧培养24 h后,离心收集菌体沉淀,经适当稀释调整,使菌体浓度分别为1.0×109 cfu/mL、1.0×108 cfu/mL、1.0×107 cfu/mL和1.0×106cfu/mL,同时根据《食品添加剂使用标准(GB276 0-2014)》规定,胭脂红色素在食品中的最大允许使用量为0.05g /kg,设置胭脂红色素在含B153菌体的MRS液体培养基中的浓度分别为0.05、0.025和0.0125 g/L,于不同培养时间(3 h ~ 48 h)下取培养液,与1.5 g/L乙酸铵溶液按1:1比例稀释,在505 nm下测吸光值,按照下述公式计算降解率。
实验结果如下:
表9 不同培养时间下发酵乳杆菌B153菌株对胭脂红色素的降解效果
表9结果显示,发酵乳杆菌B153菌株对苋菜红色素具有明显的降解效果,在培养时间为24 h、36 h和48 h,菌体浓度为1.0×109 cfu/mL,胭脂红色素浓度为0.05 g/L时,B153菌株对苋菜红色素的降解率超过50%,分别为57.90%、63.55%和72.18%。
实施例11 发酵乳杆菌(Lactobacillus fermentum)B153在降解诱惑红色素中的应用
实验方法:将菌株B153(菌体浓度为1.0×107 cfu/mL)按体积比5%的接种量分别接种于MRS液体培养基中,置于37℃下厌氧培养24 h后,离心收集菌体沉淀,经适当稀释调整,使菌体浓度分别为1.0×109 cfu/mL、1.0×108 cfu/mL、1.0×107 cfu/mL和1.0×106cfu/mL,同时根据《食品添加剂使用标准(GB276 0-2014)》规定,诱惑红色素在食品中的最大允许使用量为0.025 g/kg,设置诱惑红色素在含B153菌体的MRS液体培养基中的浓度分别为0.025、0.0125和0.00625 g/L,于不同培养时间(3 h ~ 48 h)下取培养液,与1.5 g/L乙酸铵溶液按1:1比例稀释,在500 nm下测吸光值,按照下述公式计算降解率。
实验结果如下:
表10 不同培养时间下发酵乳杆菌B153菌株对诱惑红色素的降解效果
表10结果显示,发酵乳杆菌B153菌株对诱惑红色素具有一定的降解效果,在培养时间为48 h,菌体浓度为1.0×109 cfu/mL,诱惑红色素浓度为0.025 g/L时,B153菌株对诱惑红色素的降解率为50.93%。
综上所述,本发明提供的发酵乳杆菌B153具有很强的耐酸耐胆盐能力、较高的植酸酶活力、对致病菌创伤弧菌的生长具有明显的抑制作用,该菌株对偶氮类人工合成使用色素(柠檬黄、日落黄、柠檬黄、苋菜红、胭脂红和诱惑红)具有一定的降解效果。鉴于发酵乳杆菌是我国批准的可用于普通食品的菌种之一,且分离自人类母乳,安全性很高,所以本发明提供的发酵乳杆菌B153具有很高的实际应用价值。
以上仅是本发明的若干个具体实施例。
本发明不限于以上实施例,还可以有许多变形。本领域的普通技术人员能从本发明公开的内容直接导出或联想到的所有变形,均应认为是本发明的保护范围。
SEQUENCE LISTING
<110> 福建省农业科学院农业工程技术研究所
<120> 一株发酵乳杆菌及其应用
<130>
<160> 3
<170> PatentIn version 3.3
<210> 1
<211> 20
<212> DNA
<213> 人工序列
<400> 1
agagtttgat cctggctcag 20
<210> 2
<211> 19
<212> DNA
<213> 人工序列
<400> 2
ggttaccttg ttacgactt 19
<210> 3
<211> 1378
<212> DNA
<213> 人工序列
<400> 3
aacgagtggc ggacgggtga gtaacacgta ggtaacctgc ccagaagcgg gggacaacat 60
ttggaaacag atgctaatac cgcataacag cgttgttcgc atgaacaacg cttaaaagat 120
ggcttctcgc tatcacttct ggatggacct gcggtgcatt agcttgttgg tggggtaatg 180
gcctaccaag gcgatgatgc atagccgagt tgagagactg atcggccaca atgggactga 240
gacacggccc atactcctac gggaggcagc agtagggaat cttccacaat gggcgcaagc 300
ctgatggagc aacaccgcgt gagtgaagaa gggtttcggc tcgtaaagct ctgttgttaa 360
agaagaacac gtatgagagt aactgttcat acgttgacgg tatttaacca gaaagtcacg 420
gctaactacg tgccagcagc cgcggtaata cgtaggtggc aagcgttatc cggatttatt 480
gggcgtaaag agagtgcagg cggttttcta agtctgatgt gaaagccttc ggcttaaccg 540
gagaagtgca tcggaaactg gataacttga gtgcagaaga gggtagtgga actccatgtg 600
tagcggtgga atgcgtagat atatggaaga acaccagtgg cgaaggcggc tacctggtct 660
gcaactgacg ctgagactcg aaagcatggg tagcgaacag gattagatac cctggtagtc 720
catgccgtaa acgatgagtg ctaggtgttg gagggtttcc gcccttcagt gccggagcta 780
acgcattaag cactccgcct ggggagtacg accgcaaggt tgaaactcaa aggaattgac 840
gggggcccgc acaagcggtg gagcatgtgg tttaattcga agctacgcga agaaccttac 900
caggtcttga catcttgcgc caaccctaga gatagggcgt ttccttcggg aacgcaatga 960
caggtggtgc atggtcgtcg tcagctcgtg tcgtgagatg ttgggttaag tcccgcaacg 1020
agcgcaaccc ttgttactag ttgccagcat taagttgggc actctagtga gactgccggt 1080
gacaaaccgg aggaaggtgg ggacgacgtc agatcatcat gccccttatg acctgggcta 1140
cacacgtgct acaatggacg gtacaacgag tcgcgaactc gcgagggcaa gcaaatctct 1200
taaaaccgtt ctcagttcgg actgcaggct gcaactcgcc tgcacgaagt cggaatcgct 1260
agtaatcgcg gatcagcatg ccgcggtgaa tacgttcccg ggccttgtac acaccgcccg 1320
tcacaccatg agagtttgta acacccaaag tcggtggggt aacctttagg agccagcc 1378
Claims (8)
1.一株发酵乳杆菌(Lactobacillus fermentum)B153,其特征在于:所述菌株于2018年9月10日保藏在中国微生物菌种保藏管理委员会普通微生物中心,保藏地址为:北京市朝阳区北辰西路1号院3号,保藏编号为:CGMCC No.16454。
2.根据权利要求1所述的发酵乳杆菌,其特征在于:所述菌株的形态特征为:在MRS平板培养基上培养24~48 h后,菌落呈圆形,乳白色,表面光滑、隆起,边缘整齐,不透明;菌体呈杆状,大小为0.3~0.6 × 1.0~3.0 μm。
3.一种如权利要求1所述的发酵乳杆菌在制备抑制创伤弧菌药物、保健食品或普通食品中的应用。
4.根据权利要求3所述的应用,其特征在于,所述药物、保健食品或普通食品中所含发酵乳杆菌B153的活菌数为1.0×106-5.0×1011 cfu/mL或1.0×106-5.0×1011 cfu/g。
5.根据权利要求3所述的应用,其特征在于,所述药物、保健食品或普通食品中所含发酵乳杆菌B153的活菌数为2.0×106-2.0×108 cfu/mL或2.0×106-2.0×108 cfu/g。
6.根据权利要求3所述的应用,其特征在于,所述药物、保健食品或普通食品中所含发酵乳杆菌B153的活菌数为2.0×107 cfu/mL或2.0×107 cfu/g。
7.一种如权利要求1所述的发酵乳杆菌在制备低植酸产品中的应用。
8.一种如权利要求1所述的发酵乳杆菌在降解偶氮类人工合成色素中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111175711.9A CN113717900B (zh) | 2021-10-09 | 2021-10-09 | 一株发酵乳杆菌及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111175711.9A CN113717900B (zh) | 2021-10-09 | 2021-10-09 | 一株发酵乳杆菌及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113717900A true CN113717900A (zh) | 2021-11-30 |
CN113717900B CN113717900B (zh) | 2023-02-14 |
Family
ID=78685700
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111175711.9A Active CN113717900B (zh) | 2021-10-09 | 2021-10-09 | 一株发酵乳杆菌及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113717900B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117143767A (zh) * | 2023-08-23 | 2023-12-01 | 浙江民生健康科技有限公司 | 可调节肠道菌群的母乳源发酵粘液乳杆菌msjk0025及其应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008068341A1 (fr) * | 2006-12-08 | 2008-06-12 | Compagnie Gervais Danone | Produit alimentaire comprenant des probiotiques et un monoacide faible protoné |
US7858336B1 (en) * | 2010-02-01 | 2010-12-28 | Microbios, Inc. | Process and composition for the manufacture of a microbial-based product |
CN109161509A (zh) * | 2018-10-10 | 2019-01-08 | 中国农业科学院兰州兽医研究所 | 一株能防治牛羊腹泻病的菌株 |
CN110684697A (zh) * | 2019-11-13 | 2020-01-14 | 山东农业大学 | 一种具有抗氧化功能的发酵乳杆菌jx306及其用途 |
-
2021
- 2021-10-09 CN CN202111175711.9A patent/CN113717900B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008068341A1 (fr) * | 2006-12-08 | 2008-06-12 | Compagnie Gervais Danone | Produit alimentaire comprenant des probiotiques et un monoacide faible protoné |
US7858336B1 (en) * | 2010-02-01 | 2010-12-28 | Microbios, Inc. | Process and composition for the manufacture of a microbial-based product |
CN109161509A (zh) * | 2018-10-10 | 2019-01-08 | 中国农业科学院兰州兽医研究所 | 一株能防治牛羊腹泻病的菌株 |
CN110684697A (zh) * | 2019-11-13 | 2020-01-14 | 山东农业大学 | 一种具有抗氧化功能的发酵乳杆菌jx306及其用途 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117143767A (zh) * | 2023-08-23 | 2023-12-01 | 浙江民生健康科技有限公司 | 可调节肠道菌群的母乳源发酵粘液乳杆菌msjk0025及其应用 |
CN117143767B (zh) * | 2023-08-23 | 2024-06-11 | 浙江民生健康科技有限公司 | 可调节肠道菌群的母乳源发酵粘液乳杆菌msjk0025及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN113717900B (zh) | 2023-02-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110878270B (zh) | 一株副干酪乳杆菌副干酪亚种及其应用 | |
CN103602608B (zh) | 短小芽孢杆菌在对虾养殖中的应用 | |
CN104651268A (zh) | 一种植物乳杆菌及其应用 | |
CN103289933A (zh) | 解淀粉芽孢杆菌植物亚种b-01及其应用 | |
CN114921385B (zh) | 一种枯草芽孢杆菌及其在饲料添加和无抗养殖中的应用 | |
CN116179440B (zh) | 一株鸡源贝莱斯芽孢杆菌及其应用 | |
KR20120126917A (ko) | 바실러스 섭틸리스 in-55, 락토바실러스 플란타룸 bt-77 및 이를 이용한 사일리지 제조방법 | |
CN110172420B (zh) | 一株鼠李糖乳杆菌及其应用 | |
CN113943670B (zh) | 一株防病促生长托拉斯假单胞菌及其应用 | |
CN113717900B (zh) | 一株发酵乳杆菌及其应用 | |
CN113558069B (zh) | 一株捕食植物病原菌的黏细菌h56d21及其应用 | |
CN107937301B (zh) | 一种解淀粉芽孢杆菌及其在水产养殖中的应用 | |
CN117106676B (zh) | 一株枯草芽孢杆菌及其在饲料生产中的应用 | |
CN117070428B (zh) | 枯草芽孢杆菌bs-22株在改善养殖环境中的应用 | |
CN116656579B (zh) | 一株海洋产酶细菌新种菌株及其应用 | |
KR101854705B1 (ko) | 알파글루코시다아제 저해제를 다량 생산하는 바실러스 리케니포르미스 ny1505 균주 | |
KR100233615B1 (ko) | 액체발효에 의한 비스판균의 제조방법 | |
CN113061550B (zh) | 一株乳杆菌新菌株z6及其在食品中的应用 | |
CN111647523B (zh) | 一种刺参养殖用益生菌组合物及其应用 | |
CN111411053B (zh) | 一株协同产三种抗细菌代谢产物枯草芽孢杆菌jcl16及其筛选和应用 | |
KR20220162899A (ko) | 식물 생장 촉진 및 식물병 방제 활성을 갖는 마이크로박테리움 테스타세움 ddp398 균주 및 이의 용도 | |
KR101477886B1 (ko) | 갯지렁이로부터 동정된 이종의 바실러스 균주를 이용한 갯벌정화제 | |
CN114836338B (zh) | 一株鼠李糖乳杆菌a5及其应用 | |
KR102482101B1 (ko) | 폐사어 발효물 내 gaba 함량을 증가시키는 바실러스 서브틸리스 jc-03 균주 및 이의 용도 | |
KR101447423B1 (ko) | 갯지렁이로부터 동정된 내염성 및 에스테라아제 활성을 갖는 바실러스 신규 균주 및 이를 이용한 유기물 정화제 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20230607 Address after: 361199 No. 570, Tongji North Road, Tong'an District, Xiamen City, Fujian Province Patentee after: XIAMEN YUANZHIDAO BIOTECH CO.,LTD. Address before: 350003 No. 54, 247 North Road, Gulou District, Fujian, Fuzhou Patentee before: INSTITUTE OF AGRICULTURAL ENGINEERING TECHNOLOGY, FUJIAN ACADEMY OF AGRICULTURAL SCIENCES |